Ascentage Pharma announced on April 23, 2025, that results from two clinical studies of its key drug candidates, lisaftoclax (APG-2575) and alrizomadlin (APG-115), were selected for presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
These presentations will include an oral report featuring updated results from a Phase Ib/II study of a lisaftoclax combination regimen in patients with myeloid malignancies. Additionally, data on alrizomadlin monotherapy and combinations in solid tumors will be presented.
The ASCO Annual Meeting is a prominent scientific gathering in clinical oncology, and these presentations highlight the strength of Ascentage Pharma's clinical development and global innovation efforts. The company aims to bring more treatment options to patients with unmet needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.